PIRS - Pieris Pharmaceuticals Inc
IEX Last Trade
18.055
-0.415 -2.299%
Share volume: 9,135
Last Updated: Fri 30 Aug 2024 08:44:37 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$18.47
-0.42
-2.25%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-04 | 2023-03-31 | 2023-05-11 | 2023-08-10 | 2023-11-14 | 2024-03-29 | 2024-05-15 | |
| Assets | |||||||||
| Total Assets | 114.309 M | 99.163 M | 95.490 M | 82.258 M | 87.544 M | 59.376 M | 38.680 M | 29.497 M | |
| Current Assets | 90.904 M | 78.560 M | 73.424 M | 60.505 M | 66.472 M | 59.089 M | 38.680 M | 29.497 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 8.704 M | 7.908 M | 8.445 M | 11.071 M | 10.645 M | 11.136 M | 4.087 M | 2.972 M | |
| Short Term Investments | 8.704 M | 7.908 M | 8.445 M | 11.071 M | 10.645 M | 11.136 M | 4.087 M | 2.972 M | |
| Total Receivables | 1.264 M | 829.000 K | 5.810 M | 1.055 M | 952.000 K | 1.045 M | 6.039 M | 7.245 M | |
| Current Cash | 80.936 M | 69.823 M | 59.169 M | 48.379 M | 54.875 M | 44.810 M | 26.366 M | 19.084 M | |
| Total Non-current Assets | 23.405 M | 20.603 M | 22.066 M | 21.753 M | 21.072 M | 287.000 K | 0.000 | 0.000 | |
| Property Plant Equipment | 17.430 M | 15.897 M | 16.992 M | 16.706 M | 16.163 M | 0.000 | 0.000 | 0.000 | |
| Other Assets | 5.975 M | 4.706 M | 5.074 M | 5.047 M | 4.909 M | 287.000 K | 0.000 | 0.000 | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 114.309 M | 99.163 M | 95.490 M | 82.258 M | 87.544 M | 59.376 M | 38.680 M | 29.497 M | |
| Total liabilities | 69.944 M | 63.396 M | 67.561 M | 66.800 M | 47.046 M | 28.866 M | 11.922 M | 7.533 M | |
| Total current liabilities | 35.546 M | 33.521 M | 36.583 M | 42.875 M | 34.369 M | 28.866 M | 11.922 M | 7.533 M | |
| Accounts Payable | 1.898 M | 3.641 M | 4.154 M | 5.833 M | 7.604 M | 2.816 M | 3.372 M | 1.518 M | |
| Other liabilities | 22.063 M | 18.484 M | 18.734 M | 11.727 M | 759.000 K | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 12.292 M | 0.000 | 0.000 | |
| Long term debt | 12.335 M | 11.391 M | 12.244 M | 12.198 M | 11.918 M | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 22.063 M | 18.484 M | 18.734 M | 11.727 M | 759.000 K | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 44.365 M | 35.767 M | 27.929 M | 15.458 M | 40.498 M | 30.510 M | 26.758 M | 21.964 M | |
| Common stock | 74.125 M | 74.397 M | 74.455 M | 74.519 M | 87.639 M | 98.852 M | 1.241 M | 1.237 M | |
| Retained earnings | -272.583 M | -282.319 M | -290.421 M | -303.604 M | -299.628 M | -310.380 M | -314.964 M | -319.856 M |